左旋門(mén)冬酰胺酶（L-ASP）作為兒童急性淋巴細(xì)胞白血病治療聯(lián)合化療方案中的最基本藥物之一，在對(duì)維持患兒長(zhǎng)期處于帶病生存狀態(tài)中起著極為重要的作用。但長(zhǎng)期以來(lái)其在兒童臨床應(yīng)用的安全性也一直是人們關(guān)注的重點(diǎn)。就近些年L-ASP在國(guó)內(nèi)外兒童臨床應(yīng)用引起不良反應(yīng)的類型、原因以及發(fā)展方向等方面的研究進(jìn)展進(jìn)行綜述。

L-asparaginase (L-ASP), one of the most basic drugs in the treatment of acute lymphocytic leukemia (ALL) for children, has played an extremely important role for maintaining the long-term event-free survival rates in ALLfor children. However, the side effects caused by L-ASP have also been concerned. In this paper, the progress in studies on types and reasons of the side effects of L-ASP in the treatment of ALL for children and its development direction are reviewed.